# Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Study · id `cardio:ct-nct01426802` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01426802](<https://clinicaltrials.gov/study/NCT01426802>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01426802

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT01426802. Allocation not applicable; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT01426802, source copy `cardio:ctgov-nct01426802-2017-02-27`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01426802, source copy `cardio:ctgov-nct01426802-2017-02-27`, retrieved 2026-10-26)
- Primary completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01426802, source copy `cardio:ctgov-nct01426802-2017-02-27`, retrieved 2026-10-26)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01426802, source copy `cardio:ctgov-nct01426802-2017-02-27`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT01426802, source copy `cardio:ctgov-nct01426802-2017-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01426802-2017-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): vildagliptin
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 964607661efab97fe5d8e37b81743e9292f46739a1b24a82cff6d8b8589a4ae0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
